Screener
Alnylam Pharmaceuticals ALNY Proceeds from restricted investments
Proceeds from restricted investments at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfRestrictedInvestments.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of property, plant and equipment | (56,513) | (23,263) |
| Purchases of marketable securities | (837,297) | (861,199) |
| Sales and maturities of marketable securities | 485,986 | 856,850 |
| Proceeds from maturity of restricted and other investments | 66,725 | 58,075 |
| Purchases of restricted and other investments | (22,000) | (58,075) |
| Other investing activities | (25,900) | — |
| Net cash used in investing activities | (388,999) | (27,612) |
| Cash flows from financing activities: |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's proceeds from restricted investments?
- Alnylam Pharmaceuticals (ALNY) reported proceeds from restricted investments of $17.9M in Q2 2026.
- How has Alnylam Pharmaceuticals's proceeds from restricted investments changed year-over-year?
- Alnylam Pharmaceuticals's proceeds from restricted investments increased by 93.5% year-over-year, from $9.25M to $17.9M.
- What is the long-term trend for Alnylam Pharmaceuticals's proceeds from restricted investments?
- Over 2 years (2021 to 2025), Alnylam Pharmaceuticals's proceeds from restricted investments has grown at a 19.3% compound annual growth rate (CAGR), from $41.98M to $59.78M.
- What does proceeds from restricted investments mean?
- This represents cash inflows resulting from the maturity or sale of investment assets that are legally or contractually restricted from general corporate use. These assets are typically held to satisfy specific collateral requirements, debt covenants, or long-term project obligations. Tracking these proceeds helps investors understand the liquidity available from restricted pools to support ongoing capital needs.
Ask your AI about Alnylam Pharmaceuticals's proceeds from restricted investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude